Immunohistochemical Expression of CXCL5 as a Valuable Prognostic Marker in Urinary Bladder Urothelial Carcinoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-01-01

Study Completion Date

2022-07-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Urothelial carcinoma is common malignant tumor worldwide, it remains a challenge in the oncology field, it is an ideal for research on biomarkers that could identify tumor progression and prognosis. CXCL5 have been implicated in progression of many cancers, but their significance in urinary bladder UC remains unclear.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

SOX2 & PDL1 Expression on Urinary Bladder Carcinoma

NCT05429710

Urinary Bladder Neoplasm

UNKNOWN

Prognostic Biomarkers in Patients With Urothelial Carcinoma

NCT04872036

Bladder Cancer

COMPLETED

Urothelial Cancer Tumor Bio-markers and Physical-spectroscopic Characteristic

NCT04770974

Urothelial Carcinoma Bladder Cancer Urothelial Neoplasm +2 more

UNKNOWN

Microbiota in Urine and Urothelium Can be a Factor for Induction of Urinary Bladder Cancer. The Study Will Examine Urine and Bladder Tissues From Egyptian Male Patients and Controls Using Whole Genomic Sequencing Techniques and 16S rRNA. The Aim is to Elucidate Role of Microbiota in Bladder Cancer.

NCT06289270

Microbiota in Patients With Urinary Bladder Carcinoma in Urine and Cancer Tissues

RECRUITING

Outcome of Treating Bladder Cancer in Sohag University Hospital

NCT05082818

Bladder Cancer

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Bladder carcinoma has become a common cancer globally, Incidence rates are highest in Europe, the United States and Egypt. In Egypt, bladder carcinoma was considered the third most common tumor; Egyptian males have the highest mortality rates. UC of the urinary bladder represents about 90% of all bladder cancers.

CXCL5 is a chemokine, belonging to ‗ELR+' subgroup. It plays an important role in angiogenesis and tumor migration. Numerous reports have indicated that CXCL5 plays important roles in cancer progression, including cholangiocarcinoma, prostate cancer, and gastric cancer. Studying the IHC expression of CXCL5 in UC to assess its role in tumor cell proliferation, migration and spread is needed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Urinary Bladder Urothelial Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\-

Exclusion Criteria

* \- Patients received pre-operative chemotherapy or radiotherapy.
* Patients with insufficient clinical data.
* Specimens with extensive necrosis
* Tiny specimens which are insufficient for accurate diagnosis.

Eligible Sex

ALL

Accepts Healthy Volunteers

No